Department of Health and Human Services, through National Institutes of Health, awarded Rise Therapeutics LLC of Rockville, MD $1,042,478 under the SBIR program (Phase I), with work starting 2026-09-01 and running to 2028-08-31. It is one of 3 SBIR and STTR awards Rise Therapeutics LLC received in the last two years, $2,021,469 in all. Each figure links to the federal record.
The award
| Recipient | Rise Therapeutics LLC (Rockville, MD) |
|---|---|
| Awarding agency | Department of Health and Human Services |
| Awarding office | National Institutes of Health |
| Phase | Phase I |
| Amount obligated | $1,042,478 |
| Period of performance starts | 2026-09-01 |
| Period of performance ends | 2028-08-31 |
| Award number | R44DK146369 (grant, CFDA 93.847) |
| Assistance listing | 93.847, Diabetes, Digestive, and Kidney Diseases Extramural Research |
| Place of performance | Rockville, Montgomery County, MD |
| Signed | 2026-09-03 |
| Recipient registry id (UEI) | N36JMJ1DKWH6 |
Want the whole picture on Rise Therapeutics LLC?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Rise Therapeutics LLC: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Rise Therapeutics LLC covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
21 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What it is for
A novel immunological-directed live biotherapy product for treating crohn's disease - project summary the goal of this project is to evaluate the safety and clinical efficacy of R-3750, an engineered live biotherapeutic
Funding actions on this award
| Date | Action | Modification | Amount |
|---|---|---|---|
| 2026-09-03 | New | 000 | $1,042,478 |
A novel immunological-directed live biotherapy product for treating crohn's disease - project summary the goal of this project is to evaluate the safety and clinical efficacy of R-3750, an engineered live biotherapeutic product (lbp) designed to modulate intestinal immune responses and restore gut homeostasis, in patients with crohn’s disease (cd). This proposal is based on the promising safety profile and initial clinical activity observed in the ongoing phase 1 trial for ulcerative colitis (uc). Given the overlapping immunological pathways between cd and uc, R-3750 represents a novel therapeutic approach with the potential to address critical gaps in cd treatment. An estimated 800,000 to 1 million adults in the u.s. Suffer from cd, a chronic inflammatory disorder of the gastrointestinal tract. Cd is typically diagnosed in young adulthood but can develop at any age, is life-long, and has no cure. Current treatments can have significant side effects, and many patients become refractory to available therapies. There is an urgent need for novel, targeted interventions that restore the integrity of the intestinal barrier, regulate immune responses, and modulate the gut microbiome. Intestinal immune regulation is essential for maintaining gut homeostasis, and its disruption is central to cd pathogenesis. The human microbiome plays a crucial role in this regulation, with commensal b ...
From the federal award record.
Other SBIR and STTR awards to Rise Therapeutics LLC
| Starts | Agency | Program | Amount | Project |
|---|---|---|---|---|
| 2025-08-14 | Department of Health and Human Services | SBIR Phase I | $429,158 | A novel immunological-directed probiotic for the treatment of sjögren’s syndrome - project (record) |
| 2025-08-14 | Department of Health and Human Services | SBIR Phase I | $549,833 | A novel immunological-directed probiotic for the treatment of sjögren’s syndrome - project (record) |
Every other federal award to Rise Therapeutics LLC on record
The federal register lists 18 other awards to the same registry id (UEI N36JMJ1DKWH6), $33,686,094 in all, from 1 agency.
| Starts | Agency | Amount | Award |
|---|---|---|---|
| 2026-09-16 | National Institutes of Health | $740,140 | Clinical validation of a synthetic biology-based microbial medicine to treat immunotherapy refractory solid tu (R44CA306440) |
| 2024-09-16 | National Institutes of Health | $2,189,306 | A novel synthetically engineered oral immunotherapy for treating ulcerative colitis - project summary the goal (SB1DK141356) |
| 2023-09-04 | National Institutes of Health | $3,402,395 | A novel immunological-directed biotherapy for treating rheumatoid arthritis - project summary our goal is to d (R44AG084484) |
| 2023-09-01 | National Institutes of Health | $1,995,869 | R-5280, a novel modified superior resistant starch therapy for type 1 diabetes - project summary type 1 diabet (R44DK137649) |
| 2023-04-24 | National Institutes of Health | $2,090,261 | A novel immunological-directed synthetic biology-based drug for the treatment of multiple sclerosis - project (R44AI174844) |
| 2023-01-17 | National Institutes of Health | $2,005,073 | A novel synthetic biology-derived microbiome therapeutic to treat viral-induced acute respiratory distress syn (R44AI174332) |
| 2022-07-15 | National Institutes of Health | $282,514 | A novel probiotic drug delivery platform for oral administration of protein-based therapies - project summary (R43TR004300) |
| 2022-07-05 | National Institutes of Health | $2,277,236 | A novel immunological-directed live biotherapy product for treating ulcerative colitis - project summary the g (R44DK133061) |
| 2022-07-01 | National Institutes of Health | $2,083,016 | A novel immunologically directed probiotic for the treatment of type 1 diabetes - project summary our goal is (R44DK134274) |
| 2021-05-12 | National Institutes of Health | $2,918,422 | A novel probiotic for the treatment of sjogren's syndrome - project summary our goal is to develop a novel, im (SB1DE030833) |
| 2021-04-01 | National Institutes of Health | $2,436,171 | A novel microbiome-based immune-modulator that potentiates cancer checkpoint therapy - project summary the goa (R44CA261509) |
| 2021-02-23 | National Institutes of Health | $2,922,693 | A novel immunologically enhanced probiotic for treating rheumatoid arthritis - project summary our goal is to (R44AI157031) |
| 2020-07-01 | National Institutes of Health | $2,845,003 | A novel engineered probiotic for the prevention of clostridium difficile infection (R44AI152670) |
| 2019-02-15 | National Institutes of Health | $516,894 | A novel probiotic engineered for enhanced immunological function for treating inflammatory bowel disease (R43AI142975) |
| 2018-07-01 | National Institutes of Health | $2,294,488 | A novel immunological probiotic for treating inflammatory bowel disease (R44DK117726) |
| 2018-07-01 | National Institutes of Health | $480,497 | A novel immunological probiotic for treating inflammatory bowel disease (R43DK117726) |
| 2018-02-06 | National Institutes of Health | $299,953 | A novel probiotic for preventing and treating clostridium difficile pathogenesis (R43AI138681) |
| 2016-08-02 | National Institutes of Health | $1,906,163 | A novel probiotic for the treatment of sjogren's syndrome (R44DE026379) |
Who runs it, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Rise Therapeutics LLCLook up Rise Therapeutics LLC first. Finding the company and seeing how much is on record uses no credits.
Look up Rise Therapeutics LLCWhere this comes from
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs set aside part of federal research budgets for small companies. Agencies award them in phases: Phase I tests whether an idea is feasible, Phase II funds development, and Phase III is follow-on work paid for outside the set-aside. STTR awards also require a research institution as a partner.
Every figure on this page is taken from the award's own federal record, linked beside it, as it stood when the page was built: the recipient, its address, the awarding agency and office, the amount obligated so far, the dates and the description. Phase and program are shown as the award's own description states them. The amount can grow later if the agency adds funding to the same award.